C Difficile

Request PDF | Preoperative Oral Antibiotics Preparation is Associated With Improved 30-day Outcomes in Elective Colectomy for Ulcerative Colitis | Background Ulcerative colitis (UC) is characterized by colonic involvement, where the 10-year risk of colectomy remains high at about 20%. The use... | Find, read and cite all the research you need on ResearchGate

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile Infection.

Published study validates ibezapolstat's unique mechanism preserving beneficial gut bacteria while targeting C. difficile, advancing to Phase 3 trials with regulatory fast-track status.

Food microbiologist Dennis D’Amico demonstrated that bacteriophages can effectively reduce the amount of common foodborne pathogens in milk

The results demonstrated that tagatose consumption not only proved safe for animals but also significantly reduced infection symptoms and severity

Request PDF | Clostridioides (Clostridium) difficile infection in hospitalized adult patients in Cambodia | Despite high levels of global concern, little is known about the epidemiology of Clostridioides ( Clostridium ) difficile infection (CDI) in... | Find, read and cite all the research you need on ResearchGate

Microbiota transplantation is safe and effective for treating clostridioides difficile infections, according to a clinical trial published in the journal Gastroenterology.

A group of gut bacteria successfully hindered recurrent Clostridium difficile infection in mice, offering alternative therapeutic strategies to antibiotics and fecal transplant.

A synthetic microbiome therapy, tested in mice, holds promise as a new treatment for C. difficile, a notoriously difficult-to-treat bacterial infection, according to a team of researchers at Penn State. The targeted treatment was as effective as human fecal transplants in mice against C. difficile infection with fewer safety concerns, protecting against severe symptoms and decreasing recurrent infections.

Background Antibiotics are broadly prescribed for community-acquired pneumonia (CAP) despite being only effective for bacterial infections. LIAISON® MeMed BV® (LMMBV) is a novel diagnostic test that can support clinicians in differentiating bacterial from viral infections and guide diagnostic-driven antibiotic prescribing. Methods We developed a cost-impact model to compare the clinical and economic outcomes of using LMMBV with the current standard of care (SOC) versus SOC alone among a hypothetical cohort of 1,000 CAP patients presenting to the emergency department. The analysis was conducted from a Canadian public health payer’s perspective. Outcomes of interest included antibiotic use (number of patients and days saved), hospital admission (admissions avoided and days saved), intensive care unit admission, adverse events, and clostridium difficile infection. One-way sensitivity analyses were conducted to explore parameter uncertainty. Scenario analyses were conducted according to age group, province, and impact of LMMBV on hospitalization. Results In the base case, LMMBV plus SOC reduced the number of patients prescribed antibiotic treatment (429 patients avoided) and the total number of antibiotic treatment days (1,020 days avoided). The per-patient cost savings were $504.96 compared to SOC alone. These findings were consistent across all sensitivity and scenario analyses. Assuming full adoption of LMMBV, the per patient cost savings are projected to result in more than $163 million in total savings annually in Canada based on population estimates and published incidence data. Conclusion Considering the burden of CAP and antimicrobial resistance to the health care system, the use of LMMBV with SOC can offer both clinical and economic benefits to Canadian public payers.

A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously difficult-to-treat and potentially life threatening in humans, according to a team of researchers at Penn State.

Fidaxomicin was clinically effective compared to vancomycin. Fidaxomicin is often reported as cost-effective, consistently within high-risk subpopulations.

Clostridioides difficile infections are difficult and serious problem occurring in patients staying in intensive care units. In recent years, the numb…

What Are the Projected Growth and Market Size Trends for the Zinplava Market In recent times the zinplava market has seen a XX CAGR expansion Predicted growth indicates an increase from XX million in 2024 to XX million in 2025 ...

Fidaxomicin was clinically effective compared to vancomycin. Fidaxomicin is often reported as cost-effective, consistently within high-risk subpopulations.

spaniClostridioides difficile/i is a significant cause of diarrhea worldwide, initially as a hospital-acquired infection and, more recently, as a community-associated infection. Risk factors for hospital-acquired iC. difficile/i infection include antimicrobial consumption, extended hospitalizati/span …

Objective The objective of this study is to investigate the predisposing factors, disease course, potential complications, role of primary prophylaxis, and overall clinical outcomes of iClostridioides difficile/i infection (CDI) in cancer patients. Methods The study was conducted at Shaukat Khan …

The major risk factors associated with CDI in IBD patients were IBD activity before infection, UC and colonic Crohn's disease, short duration of IBD, corticosteroid usage, and hospitalization. Patients with active IBD and a shorter disease duration may benefit from more frequent follow-ups in the ea …

Chronic kidney disease (CKD) may be associated with dysbiosis which may increase the risk of gastrointestinal infections. Patients with kidney failure have a predominance of bacteria responsible for the exacerbation of chronic inflammation through the production of ureases, uricase, and uremic toxin …

Clostridioides difficile infections are the leading cause of healthcare-associated diarrhea. C. difficile poses a risk to public health due to its ability to form spores and cause recurrent infections. Glycolipids make up ~50% of the polar lipids in the C. difficile membrane, a …

We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for Clostridioides difficile infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functional …

Clostridioides difficile is a significant cause of diarrhea worldwide, initially as a hospital-acquired infection and, more recently, as a community-associated infection. Risk factors for hospital-acquired C. difficile infection include antimicrobial consumption, extended hospitalizati …

The models achieve high discrimination performance (AUROC 0.83). There is a general consensus among different analysis approaches regarding predictors that impact patients' chances of having a positive test, which may influence iClostridioides difficile/i risk, including features clinically …

The management costs of this study were funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Researchers have participated voluntarily and none of the investigators received funding for conducting the study.

The rapid detection and containment of healthcare-associated infections (HCAIs) is critical in preventing and controlling infectious disease outbreaks within healthcare settings. Whole genome sequencing (WGS) has emerged as a powerful tool for tracking the transmission dynamics of pathogens and when …

Clostridiodes difficile is a gram-positive, spore-forming obligate anaerobe bacillus found in the intestines of healthy individuals without signs of disease. It may cause diarrhea after antibiotic use due to the eradication of the normal gut flora. Most cases resolve with proper treatment, bu …

Albany United States As per DelveInsight s assessment globally Clostridium Difficile Infections pipeline constitutes 20 key companies continuously working towards developing 22 Clostridium Difficile Infections treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration and Developments ...